[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hanmi Pharmaceutical Company Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,66,87,113,134,154,178,200,220,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633512","phase-2-study-to-evaluate-hm15275-in-subjects-with-type-2-diabetes-mellitus-100633512",false,"NCT07527650","Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus","A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus","Key Inclusion Criteria\n\n1. Participant's age at the time of signing the informed consent:\n\n   * United States: 18 to 75 years (inclusive)\n2. Diagnosed with type 2 diabetes mellitus (T2DM) with HbA1c ≥7.0% and ≤10.0% at screening\n3. Treated with diet and exercise alone or on a stable dose of metformin (≥1000 mg\u002Fday) for at least 3 months prior to screening\n4. BMI ≥25 kg\u002Fm² and ≤50 kg\u002Fm²\n5. Body weight change \\\u003C5% over the past 3 months prior to screening\n6. Capable of giving signed informed consent and willing to comply with all protocol procedures\n\nKey Exclusion Criteria\n\n1. Type 1 diabetes mellitus or use of glucose-lowering medications other than metformin within 3 months prior to screening\n2. Poor glycemic control (fasting plasma glucose \\>270 mg\u002FdL)\n3. History of diabetic ketoacidosis or severe hypoglycemia within 6 months\n4. Clinically significant cardiovascular disease (e.g., NYHA class III\u002FIV heart failure, recent myocardial infarction, stroke, or revascularization within 3 months)\n5. History of pancreatitis or factors increasing the risk of pancreatitis\n6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2\n7. Clinically significant liver disease, renal impairment (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²), or abnormal laboratory findings at screening\n8. Participation in another investigational study within 30 days or within 5 half-lives of the investigational product, whichever is longer; for GLP-1 receptor agonist-related or weight loss studies, participation within 3 months prior to screening","ALL","18 Years","75 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.",[27,28],"Type 2 Diabetes Mellitus","T2DM",[27,28],"RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2026-05-18",{"date":38,"type":21},"2027-10",{"name":40,"class":41},"Hanmi Pharmaceutical Company Limited","INDUSTRY",10,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":47,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100641759","phase-3-a-study-to-evaluate-efficacy-and-safety-of-hcp1803-4-in-patients-with-essential-hypertension-100641759","NCT07660796","A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension","A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension","Inclusion Criteria:\n\n1. Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions\n\n   * mean sitSBP \\\u003C 180 mmHg and mean sitDBP \\\u003C 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1\n   * 140 mmHg ≤ mean sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ mean sitDBP \\\u003C 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1\n2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ mean sitDBP \\\u003C 110 mmHg at Visit 2\n\nExclusion Criteria:\n\n1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1\n2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1\n3. Orthostatic hypotension with symptoms within 3 months prior to visit 1\n4. Secondary hypertensive patient or suspected to be\n5. Clinically significant hematological finding\n6. Severe heart disease or severe neurovascular disease\n7. Moderate or malignant retinopathy\n8. Uncontrolled diabetes mellitus or type I diabetes mellitus\n9. Active gout or hyperuricemia\n10. Severe renal diseases\n11. Severe or active hepatopathy\n12. Hypokalemia or Hyperkalemia\n13. Hyponatremia or Hypernatremia\n14. Hypercalcemia\n15. History of malignancy tumor\n16. History of autoimmune disease\n17. History of alcohol or drug abuse\n18. Positive to pregnancy test, nursing mother, intention on pregnancy\n19. Considered by investigator as not appropriate to participate in the clinical study with other reason","19 Years",{"count":52,"type":21},256,[54],"PHASE3",[56],"Hypertension","NOT_YET_RECRUITING","2026-06-26",{"date":31,"type":34},{"date":61,"type":21},"2026-07-06",{"date":63,"type":21},"2027-11-30",{"name":40,"class":41},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":65},"100622108","phase-3-a-study-to-evaluate-efficacy-and-safety-of-hm11260c-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-with-metformin-and-dapagliflozin-100622108","NCT07379333","A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","Inclusion Criteria:\n\n* 1\\. Adults aged 19 years or older\n* 2\\. Diagnosed with type 2 diabetes\n* 3\\. HbA1c level 7.0% ≤ HbA1c ≤ 10.0%\n* 4\\. Stable administration of metformin (≥1,000 mg\u002Fday) and dapagliflozin (10 mg\u002Fday) without any change in dosage or formulation for at least 8 weeks prior to Visit 1\n* 5\\. 20 kg\u002Fm2 ≤ BMI ≤ 45 kg\u002Fm2\n* 6\\. Agree to the recommended exercise and diet regimen during this clinical trial\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of allergy or resistance to the investigational drug or background therapy\n* 2\\. Patients diagnosed with a type of diabetes other than type 2 diabetes\n* 3\\. Patients with uncontrolled severe diabetic complications\n* 4\\. Patients with a history of acute or chronic metabolic acidosis, including lactic acidosis or diabetic ketoacidosis.\n* 5\\. Patients with a history of diabetic coma or precoma\n* 6\\. Those with a history of severe hypoglycemia\n* 7\\. Those whose weight change \\> 5 kg\n* 8\\. History of gastrointestinal disease or surgery\n* 9\\. History of bariatric surgery\n* 10\\. History of gallbladder disease\n* 11\\. History of a disease that could affect the interpretation of HbA1c\n* 12\\. History of acute or chronic pancreatitis or pancreatectomy\n* 13\\. History (including family history) of medullary thyroid cancer (MTC) or multiple endocrine neoplasia (MEN2).\n* 14\\. Uncontrolled hypertension\n* 15\\. Severe infections or severe trauma\n* 16\\. Malnutrition, starvation, or debility, as determined by the investigator.\n* 17\\. Pituitary or adrenal insufficiency.\n* 18\\. Tissue hypoxia, such as respiratory failure or shock.\n* 19\\. History of alcoholism or drug abuse\n* 20\\. History of malignant tumors\n* 21\\. Heart failure, Ischemic heart disease, Severe cerebrovascular disease, TIA\n* 22\\. Patients with one of the following clinical laboratory test results : Amylase or Lipase \\> 3 X ULN \u002F FPG \\> 270 mg\u002FdL\n* 23\\. Patients with severe hepatic impairment or one of the following laboratory test results : AST or ALT \\> 3 X ULN \u002F Total bilirubin \\> 1.5 X ULN\n* 24\\. Patients with moderate or severe renal impairment\n* 25\\. History of Diabetic medications or weight-loss medications\n* 26\\. Those who have participated in another clinical trial and received investigational drugs within 30 days\n* 27\\. Pregnant or lactating women, or women of childbearing potential\n* 28\\. Women of childbearing potential and men who do not consent to the use of the following contraceptive methods\n* 29\\. Considered by investigator as not appropriate to participate in the clinical study with other reason.",{"count":74,"type":21},118,[54],"A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin",[78],"Type 2 Diabetes","2026-05-10",{"date":81,"type":34},"2026-05-13",{"date":83,"type":34},"2026-04-13",{"date":85,"type":21},"2028-01",{"name":40,"class":41},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":65},"100609823","phase-1-a-single-and-multiple-ascending-dose-study-of-hm17321-in-healthy-and-obese-participants-100609823","NCT07219589","A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants","A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy and Obese Participants","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* Part A: Healthy participants with BMI ≥20 kg\u002Fm² and ≤27 kg\u002Fm² at screening.\n* Part B: Healthy obese participants with BMI ≥30 kg\u002Fm² and ≤45 kg\u002Fm² at screening.\n* Stable body weight (\\\u003C5% change) in the past 3 months.\n* Able and willing to provide written informed consent.\n* Male participants must use contraception or remain abstinent from women of childbearing potential.\n* Female participants must not be pregnant or breastfeeding and use highly effective contraception if of childbearing potential.\n\nExclusion Criteria:\n\n* History of any bariatric procedure.\n* Uncontrolled thyroid disease (TSH \\>6.0 or \\\u003C0.4 mIU\u002FL).\n* Abnormal liver function or clinically significant liver disease\n\n  * Part A: ALT or AST ≥ ULN, or total bilirubin ≥ ULN\n  * Part B: ALT or AST \\>2× ULN, or total bilirubin \\>1.5× ULN\n* Abnormal pancreatic function\n\n  * Part A: amylase or lipase ≥ ULN\n  * Part B: amylase or lipase \\>3× ULN\n* Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long QT syndrome).\n* Abnormal renal function (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n* Positive test for hepatitis B, hepatitis C, or HIV at screening.\n* Women who are pregnant, planning to become pregnant, or breastfeeding.\n* History of drug or alcohol abuse within defined timeframes (e.g., alcohol \\>14 standard units\u002Fweek in past year, or positive drug screen).\n* Use of any investigational product within 30 days or 5 half-lives (whichever is longer) prior to screening.\n* Additional Exclusion Criteria for Part B\n\n  * HbA1c ≥6.5% or a history of diabetes mellitus (type 1 or type 2).\n  * Obesity induced by other endocrine disorders (e.g., Cushing syndrome).\n  * Use of weight control treatments (e.g., GLP-1 receptor agonists or other anti-obesity medications) and antihypertensive medications within 3 months prior to screening.\n  * Use of any lipid-lowering medications, unless on a stable dose for at least 3 months prior to screening.",true,"65 Years",{"count":97,"type":21},90,[99],"PHASE1","This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.",[102,103],"Obesity","Obese",[103,102],"2026-04-28",{"date":107,"type":34},"2026-05-04",{"date":109,"type":34},"2025-11-06",{"date":111,"type":21},"2027-03",{"name":40,"class":41},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100422044","phase-2-phase-2-study-to-assess-the-safety-pk-and-pd-of-sonefpeglutide-hm15912-in-sbs-if-subjects-100422044","NCT04775706","Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects","A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)","Inclusion Criteria:\n\n1. Men or women, aged 18 years of age or older with SBS resulting in intestinal failure at the time of signing the informed consent form (ICF) (or country's legal age of majority if the legal age is \\\u003C18 years)\n2. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol\n3. Diagnosis of SBS with the latest intestinal resection being at least 6 months prior to Screening and considered stable regarding the PN\u002FIV need. No restorative surgery planned in the study period.\n\nExclusion Criteria:\n\n1. Any history of colon cancer.\n2. History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free for at least 5 years\n3. History of alcohol or drug abuse (within 1 year of screening)",{"count":121,"type":21},18,[24],"This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal failure (SBS-IF).",[125],"Short Bowel Syndrome","2026-04-26",{"date":105,"type":34},{"date":129,"type":34},"2022-03-03",{"date":131,"type":21},"2028-05",{"name":40,"class":41},14,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":153,"locationsCount":42},"100534097","phase-1-dose-escalation-and-expansion-study-of-bh3120-alone-or-with-pembrolizuamb-in-advanced-or-metastatic-solid-tumors-100534097","NCT06234397","Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors","A Phase I, Open-Label, Multinational, Multicenter, Dose Escalation and Expansion Study of BH3120, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Have a Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy.\n* PD-L1 positive expression (Tumor Proportion Score ≥1% or Combined Positive Score ≥1).\n* Have at least one lesion, not previously irradiated that can be accurately measured per RECIST version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Age of 18 years or older (or country's legal age of majority if the legal age was \\>18 years)\n* Adequate Hematologic and liver function.\n\nKey Exclusion Criteria:\n\n* Has received prior therapy with an anti-4-1BB(CD137) agent.\n* Known active CNS metastases and\u002For carcinomatous meningitis.\n* Known additional malignancy that is progressing or has required active treatment.\n* History of chronic liver disease or evidence of hepatic cirrhosis.\n* History of severe toxicities associated with a prior immunotherapy.\n* Has ongoing or suspected autoimmune disease.\n* Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.",{"count":142,"type":21},245,[99],"This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part is planned to establish the MTD or RD for Dose-Expansion part, while Dose-Expansion part is designed to assess potential efficacy of BH3120, as a single agent and in combination with pembrolizumab, when administered at the RD to subjects in indication-specific expansion cohorts.",[146],"Advanced or Metastatic Solid Tumors","2026-03-09",{"date":149,"type":34},"2026-03-11",{"date":151,"type":34},"2023-12-28",{"date":85,"type":21},{"name":40,"class":41},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":42},"100627524","phase-2-belvarafenib-in-combination-with-cobimetinib-in-patients-with-locally-advanced-or-metastatic-nras-mutant-melanoma-100627524","NCT07449754","Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","A Phase 2, Multicenter, Single-Arm Study of Belvarafenib (HM95573) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","Key Inclusion Criteria:\n\n* Have histologically, cytologically confirmed locally advanced or metastatic melanoma for which no adequate standard of care exists, or for which standard of care has failed or is not tolerated.\n* Have NRAS mutation.\n* Have at least one measurable lesion at baseline per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* Age of 19 years or older\n* Adequate renal, hematologic and liver function.\n\nKey Exclusion Criteria:\n\n* Have a history of prior treatment with RAF, MEK, or ERK inhibitor.\n* Have past history or ongoing retinal pathology that is considered a risk factor for retinopathy or RVO.\n* Have past history or ongoing cardiac function-related disorders.\n* Had hemorrhage or bleeding corresponding to CTCAE Grade ≥3 within 4 weeks prior to the first dose of study drug treatment (Cycle 1 Day 1).",{"count":162,"type":21},45,[24],"This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects.\n\nTreatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.",[166],"Advanced or Metastatic Melanoma",[168,169],"NRAS-Mutant","Melanoma","2026-02-27",{"date":172,"type":34},"2026-03-04",{"date":174,"type":34},"2026-02-12",{"date":176,"type":21},"2030-03",{"name":40,"class":41},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":94,"sex":16,"minAge":50,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":65},"100615829","phase-1-a-study-to-evaluate-the-pharmacokinetics-and-safety-between-hip2503-and-hcp1306-in-healthy-volunteers-100615829","NCT07297693","A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers","An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Subjects","Inclusion Criteria:\n\n* Age 19\\~64 years in healthy volunteers\n* 18 kg\u002Fm\\^2 ≤ BMI ≤ 30 kg\u002Fm\\^2, weight(men) ≥55kg \u002F weight(women) ≥45kg\n* Agrees that the person, spouse, or partner uses appropriate medically recognized contraception and does not provide sperm or eggs from the date of administration of the first investigational drug to 14 days after the administration of the last investigational drug\n* Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial\n\nExclusion Criteria:\n\n* Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study\n* Subjects who judged ineligible by the investigator","64 Years",{"count":187,"type":21},60,[99],"The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.",[191],"Healthy","2025-12-09",{"date":194,"type":34},"2025-12-22",{"date":196,"type":21},"2025-12-19",{"date":198,"type":21},"2026-04-10",{"name":40,"class":41},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100571727","phase-1-dose-escalation-and-expansion-study-of-hm16390-alone-or-with-pembrolizumab-in-advanced-or-metastatic-solid-tumors-100571727","NCT06724016","Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors","A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390, as a Single Agent and in Combination With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Have a histologically and\u002For cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit.\n* Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patients for Dose-Ranging and Dose-Expansion Part must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before allocation or randomization.\n* Age of 18 years or older (or country's legal age of majority if the legal age was \\>18 years)\n* Adequate renal function.\n* Adequate hematologic function.\n* Adequate liver function.\n\nKey Exclusion Criteria:\n\n* Received prior treatment with agent targeting the IL-2, IL-7, or IL-15 receptors, or related to mode of action of HM16390.\n* Known active CNS metastases and\u002For carcinomatous meningitis.\n* History of severe toxicities associated with a prior immunotherapy.\n* Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per NCI-CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.\n* Has ongoing or suspected autoimmune disease.\n* Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.\n* History of chronic liver disease or evidence of hepatic cirrhosis.",{"count":208,"type":21},292,[99],"This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors.\n\nDose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potential efficacy of HM16390 as a single agent and in combination with pembrolizumab when administered at the RDEs to subjects in indication-specific expansion cohorts.",[146],{"date":213,"type":34},"2025-12-17",{"date":215,"type":34},"2024-12-11",{"date":217,"type":21},"2031-07",{"name":40,"class":41},7,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":65},"100529514","phase-3-a-study-to-evaluate-efficacy-and-safety-of-hgp2102-in-essential-hypertension-patients-100529514","NCT06174766","A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients","A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension","Inclusion Criteria:\n\n1. Subjects whose clinic blood pressure measured in visit 1 corresponds to the following conditions\n\n   * sitSBP\\\u003C180 mmHg and sitDBP\\\u003C110mg for patients receiving any BP-lowering drug within 1 month prior to Visit 1\n   * 140mmHG≤sitSBP\\\u003C180mmHg and 60mmHg≤sitDBP\\\u003C110mmHg\n2. Subjects whose clinic and ambulatory blood pressure measured in visit 2 corresponds to the following conditions\n\n   * 24h-ABPM: 130mmHg≤ SBP \\\u003C170mmHg\n   * clinic BP: 140 mmHg ≤ sitSBP \\\u003C 180 mmHg and 60 mmHg ≤ sitDBP \\\u003C 110 mmHg\n\nExclusion Criteria:\n\n1. Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1\n2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1\n3. Orthostatic hypotension with symptoms within 3 months prior to visit 1\n4. Secondary hypertension patient or suspected to be\n5. Uncontrolled type II diabetes mellitus (HbA1c \\> 9%) or type I diabetes mellitus\n6. Severe heart disease or severe neurovascular disease\n7. Moderate or malignant retinopathy\n8. Severe renal diseases (eGFR\\\u003C30mL\u002Fmin\u002F1.73m2)\n9. Severe or active hepatopathy (AST or ALT ≥ 2 times of normal range)\n10. Hypokalemia or Hyperkalemia (K\\\u003C3.5mmol\u002FL or K ≥ 5.5mmol\u002FL)\n11. Hyponatremia or Hypernatremia (Na\\\u003C135mmol\u002FL or Na ≥ 155mmol\u002FL)\n12. History of malignancy tumor\n13. History of alcohol or drug abuse\n14. Positive to pregnancy test, nursing mother, intention on pregnancy\n15. Considered by investigator as not appropriate to participate in the clinical study with other reason",{"count":228,"type":21},324,[54],"A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension",[56],"2025-06-08",{"date":234,"type":34},"2025-06-12",{"date":236,"type":34},"2024-05-10",{"date":238,"type":21},"2026-12-31",{"name":40,"class":41},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":42},"100485213","phase-1-dose-escalation-and-expansion-study-of-hm97662-in-advanced-or-metastatic-solid-tumors-100485213","NCT05598151","Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors","A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologically and\u002For cytologically confirmed advanced or metastatic solid tumor who have failed\u002Fare intolerant to standard therapy.\n* Patients for dose-escalation part must have evaluable or measurable disease at baseline and the patients for randomized dose-ranging and dose-expansion part must have at least one measurable lesion at baseline by CT or MRI per Response Evaluation Criteria in Solid Tumor (RECIST v1.1).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Life expectancy ≥ 3 months before starting HM97662.\n* Adequate renal function.\n* Adequate hematologic function.\n* Adequate liver function.\n* Males or females aged ≥ 18 years (or country's legal age of majority if the legal age was \\> 18 years) at the time of informed consent.\n* For Dose-Ranging Part, documentation of an alteration in at least one of the genes of the SWI\u002FSNF complex in tumor tissue (archival or newly obtained).\n\nExclusion Criteria:\n\n* Prior exposure to valemetostat or other EZH1\u002F2 dual inhibitor.\n* Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms.\n* Patients currently taking medications that are known strong CYP3A inhibitors and strong or moderate CYP3A inducers.\n* Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.\n* Major surgery within 4 weeks before the first dose of study drug treatment in Cycle 1.\n* Females who are pregnant or breastfeeding.\n* Patients who have undergone an organ transplant.",{"count":248,"type":21},170,[99],"This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1\u002F2 dual inhibitor, in solid tumors. The study is comprised of Dose-Escalation Part followed by randomized Dose-Ranging Part and Dose-Expansion Part. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for randomized Dose-Ranging Part. Dose-Ranging Part is designed mainly to further evaluate safety and preliminary efficacy of HM97662 monotherapy in subjects with specific genomic alterations to more precisely determine the potential RP2D that are to be tested in a Dose-Expansion Part. Dose-Expansion Part is designed to assess the potential efficacy of HM97662 monotherapy when administered at the RP2D to subjects in indication-specific expansion cohorts.",[146],"2025-04-28",{"date":254,"type":34},"2025-04-30",{"date":256,"type":34},"2023-01-11",{"date":258,"type":21},"2028-06",{"name":40,"class":41},""]